drugset / Trial / NCT03633708

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708

Phase 3 Recruiting 56 enrolled Amgen
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

Timeline

Start
2019-04-29
Primary completion
2029-01-31
Completion
2029-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Etelcalcetide Other / unclassified